A New Era for the Supply of Life-Saving Medicines: Can BFS Transform the Distribution of Biologics and Vaccines?
Blow-fill-seal (BFS) technology is being explored for one-dose presentations of vaccines and other biologics, providing a continuous, automated process that can lower manufacturing costs, increasing access for patients worldwide.
Other BFS benefits for biologics developers include enhanced automated processes with minimal human intervention, lower risk of foreign body contamination, and a high level of container integrity control during fill and finish. Manufacturers also appreciate the minimised risk of breakages during shipping and improved administration usability for clinicians and patients.
However, implementing BFS for biologics and vaccine projects comes with challenges:
- Ensuring chemical and physical compatibility of the container and the overall blow-fill-seal process with the drug formulation
- Demonstrating effective drug stability within the container
- Determining acceptable extractable and leachable profiles.
Recipharm
-
SE -
2015On CPHI since
-
5000+Employees
Other Content from Recipharm (8)
-
News Sustainability in pharmaceutical manufacturing: an expert panel discussion
In this written panel discussion experts in manufacturing in the pharmaceutical supply chain comment on the manufacturing landscape, how sustainable practices are being incorporated more readily, the challenges associated with this and the overall advantages. -
Brochure Recipharm's full service offering
Your innovative drug. Our world-class production facilities. Discover the genius of working together. -
News Recipharm receives approval for the manufacture of a new microbiome-based therapeutic
Recipharm receives regulatory approval for the manufacture of a microbiome-based product for the prevention of Clostridioides difficile recurrent infection, under GenIbet Biopharmaceuticals and Seres Therapeutics. -
News Watch now: Pharma Trends 2022 Webinar
We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event. -
News Lyophilisation technology improving thermal stability and reducing cycle times, says Recipharm expert
Lyophilisation or freeze drying is an important means to improve thermal stability of a drug product, according to Thomas Becker, Quality Director and Qualified Person, Recipharm. This is particularly true for those that are thermolabile, such as mRNA vaccine candidates.
-
Sponsored Content Key considerations to develop effective analytical methods for your drug project
A summary exploring Recipharm’s key considerations when it comes to developing effective analytical methods for drug projects. -
News CPHI Podcast Series: Selecting the Right CDMO Outsourcing Partner
With so many outsourcing options available, selecting the CDMO that is the right fit for any particular sponsor company can be a challenging task. -
News Sterile manufacturing Annex 1 amendments: what, why and how explained
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance